Skip to content

TFF PHARMACEUTICALS, INC.: 10-Q filed 2024-05-14

What TFF PHARMACEUTICALS, INC. reported in its quarterly report filed 2024-05-14 (fiscal Q1 2024): 37 published measures, 75 facts as tagged in accession 0001213900-24-042918.

This filing

Form
10-Q (quarterly report)
Filed
2024-05-14
Fiscal period
fiscal Q1 2024
Accession
0001213900-24-042918 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TFF PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-03-319,186,550USD
At 2023-12-3112,027,316USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-03-313,882,126USD
At 2023-12-312,460,282USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-03-315,304,424USD
At 2023-12-319,567,034USD
At 2023-03-3116,543,324USD
At 2022-12-3122,879,459USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-03-313,211,930USD
At 2023-12-315,478,113USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-5,735,144USD91
2023-01-01 to 2023-03-31-7,051,367USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-3,144,266USD91
2023-01-01 to 2023-03-31-4,365,783USD90

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2024-01-01 to 2024-03-31203,273USD91
2023-01-01 to 2023-03-3151,429USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-03-31901,139USD91
2023-01-01 to 2023-03-31-17,920USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-03-31-124,066,797USD
At 2023-12-31-118,331,653USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-01-01 to 2024-03-312,387,906shares91
2023-01-01 to 2023-03-311,447,723shares90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-01-01 to 2024-03-312,387,906shares91
2023-01-01 to 2023-03-311,447,723shares90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-2.4USD/shares91
2023-01-01 to 2023-03-31-4.87USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-2.4USD/shares91
2023-01-01 to 2023-03-31-4.87USD/shares90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-03-311,879,696USD
At 2023-12-311,999,781USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-03-31626,990USD91
2023-01-01 to 2023-03-31751,821USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-5,790,893USD91
2023-01-01 to 2023-03-31-7,086,446USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-03-314,862,516USD
At 2023-12-317,590,318USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-01-01 to 2024-03-3115,614USD91

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-03-313,871,270USD
At 2023-12-312,428,540USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-03-311,663,544USD
At 2023-12-31958,442USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-01-01 to 2024-03-315,994,166USD91
2023-01-01 to 2023-03-317,137,875USD90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-01-01 to 2024-03-313,555,862USD91
2023-01-01 to 2023-03-314,018,659USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-03-312,519,220shares
At 2023-12-312,370,000shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-03-313,211,930USD
At 2023-12-315,478,113USD
At 2023-03-3112,216,359USD
At 2022-12-3116,612,315USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2024-03-31-203,787USD
At 2023-12-31-148,192USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-03-3199,431USD
At 2023-12-31119,529USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-03-3195,156USD
At 2023-12-31115,254USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-03-311,983,426USD
At 2023-12-311,285,586USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-03-311,362,989USD
At 2023-12-311,678,353USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-5,790,739USD91
2023-01-01 to 2023-03-31-7,070,036USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-312,438,304USD91
2023-01-01 to 2023-03-313,119,216USD90

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2024-01-01 to 2024-03-31140,183USD91
2023-01-01 to 2023-03-31123,167USD90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-01-01 to 2024-03-3155,749USD91
2023-01-01 to 2023-03-3135,079USD90

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-01-01 to 2024-03-3115,325USD91

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-01-01 to 2024-03-3112,584USD91

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2024-01-01 to 2024-03-3122,275USD91
2023-01-01 to 2023-03-3121,488USD90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-03-31707,429USD91
2023-01-01 to 2023-03-31426,756USD90

Inspect the source

Entity
TFF PHARMACEUTICALS, INC. / CIK 0001733413
Captured
2026-09-21T17:25:24.015Z
SEC response SHA-256
831f4629fefc666a0d697443131c6e51c7c7a82a58f012a492b81a69560d76f0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001733413.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))